Indivior is a global pharmaceutical company that develops medicines to treat addiction and serious mental illnesses. The company’s vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Indivior has a global portfolio of OUD treatments, and a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. The company is headquartered in the United States in Richmond, VA, and employs more than 1,000 individuals globally. Its portfolio of products is available in 39 countries worldwide.